Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Immunol. 2012 Oct;24(5):580-4. doi: 10.1016/j.coi.2012.08.008. Epub 2012 Sep 12.

Gene therapy for primary immunodeficiencies: Part 1.

Author information

1
U768 INSERM, Paris, France. m.cavazzana@nck.aphp.fr

Abstract

Over 60 patients affected by SCID due to IL2RG deficiency (SCID-X1) or adenosine deaminase (ADA)-SCID have received hematopoietic stem cell gene therapy in the past 15 years using gammaretroviral vectors, resulting in immune reconstitution and clinical benefit in the majority of them. However, the occurrence of insertional oncogenesis in the SCID-X1 trials has led to the development of new clinical trials based on integrating vectors with improved safety design as well as investigation on new technologies for highly efficient gene targeting and site-specific gene editing. Here we will present the experience and perspectives of gene therapy for SCID-X1 and ADA-SCID and discuss the pros and cons of gene therapy in comparison to allogeneic transplantation.

PMID:
22981681
DOI:
10.1016/j.coi.2012.08.008
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center